Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) reported its second-quarter 2025 financial results and provided updates on its late-stage neuropsychiatry programs, underscoring significant advancements toward potential new treatments for major depressive disorder (MDD) and generalized anxiety disorder (GAD). The company noted strong institutional demand for its recently completed financing, which Interim CEO Eric So stated reinforces confidence in Cybin's science, differentiated therapeutic candidates, and ability to execute as it progresses toward key data readouts in 2026.
Cybin has completed enrollment in its Phase 2 study of CYB004 for GAD and continues to advance CYB003 through the Phase 3 APPROACH and EXTEND trials. Additionally, the company secured global regulatory approvals to initiate the EMBRACE Phase 3 study for adjunctive MDD treatment. These milestones represent critical steps in the development of novel treatments for mental health conditions that affect millions worldwide.
The company has also expanded its intellectual property estate to more than 100 granted patents and over 250 pending applications, reinforcing its competitive position in the neuropsychiatry space. Furthermore, Cybin's Board of Directors has formed a committee to conduct a CEO search, aiming to guide the company through its next stage of growth and late-stage clinical development.
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing next-generation treatment options for individuals suffering from mental health conditions. The company's lead candidate, CYB003, a proprietary deuterated psilocin analog, is in Phase 3 studies for adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. CYB004, a deuterated N,N-dimethyltryptamine molecule, is being studied in a Phase 2 trial for GAD. The company also maintains a research pipeline of investigational 5-HT-receptor focused compounds.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's newsroom at https://ibn.fm/CYBN.
